Cue Biopharma (CUE) EBT Margin (2018 - 2026)
Cue Biopharma (CUE) reported EBT Margin of -1113.30% for Q2 2026, down 820.99 percentage points from -292.32% a year earlier.
Powered by 
Analysis
Cue Biopharma (CUE) EBT Margin (2018 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Cue Biopharma's EBT Margin came in at -291.93%, up 183.30 percentage points year-over-year; for FY2025, it came in at -96.67%, up 350.19 percentage points from FY2024.
- EBT Margin has increased for three consecutive years, with a five-year change of +1316.58 percentage points (FY2020 to FY2025).
- By year, EBT Margin came in at -446.86% in FY2024 (+503.03 pp), -949.89% in FY2023 (+3307.97 pp), -4257.86% in FY2022 (-3965.61 pp) and -292.25% in FY2021 (+1121.01 pp).
- The Q2 2026 figure ranks as the lowest quarterly EBT Margin since Q1 2025.
- Year over year, EBT Margin gained in four of the last seven quarters, with an average year-over-year change of -278.19 percentage points.
- The high point for year-over-year EBT Margin in five years was Q2 2023 (a gain of 50160.39 percentage points); the low point was Q2 2022 (a drop of 50762.30 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 0.13% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 27.75% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 26.27% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 45.21% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 36.90% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 20.41% |
| 10 | Cue Biopharma | 98.10 Mn | 18.47 Mn | - | -1,113.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,113.30% |
| Mar 31, 2026 | -94.14% |
| Dec 31, 2025 | 9.01% |
| Sep 30, 2025 | -353.42% |
| Jun 30, 2025 | -292.32% |
| Mar 31, 2025 | -2,921.38% |
| Dec 31, 2024 | -611.23% |
| Sep 30, 2024 | -264.24% |
| Jun 30, 2024 | -390.63% |
| Mar 31, 2024 | -737.80% |
| Dec 31, 2023 | -759.58% |
| Sep 30, 2023 | -530.14% |
| Jun 30, 2023 | -961.29% |
| Mar 31, 2023 | -7,155.08% |
| Dec 31, 2022 | -9,845.03% |
| Sep 30, 2022 | -16,404.41% |
| Jun 30, 2022 | -51,138.46% |
| Mar 31, 2022 | -1,426.30% |
| Dec 31, 2021 | -95.62% |
| Sep 30, 2021 | -543.55% |
API Access
Cue Biopharma EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=CUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "CUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=CUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();